Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer
A Phase II Study of Neoadjuvant Treatment With Pegylated Liposomal Doxorubicin (Caelyx) and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Patients With Locally Advanced Breast Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Aarhus, Denmark, 8200
- Aarhus University Hospital
-
Copenhagen, Denmark, 2100
- Rigshospitalet
-
Herlev, Denmark
- Herlev Hospital
-
Odense, Denmark, 5000
- Odense University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- pathologically proven breast cancer
- inflammatory, locally advanced breast cancer or a tumor > 5 cm
- ECOG performance status < 2
- LVEF > 50% measured by MUGA (HER2 positive patients)
- adequate bone marrow, liver and renal function
- written informed consent must be obtained
Exclusion Criteria:
- another malignancy within 5 years prior to study entry
- concurrent treatment with an investigational agent
- other disease or condition that contraindicates participation in the study
- pregnant or lactating females
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
clinical response rate
Time Frame: 24 weeks
|
evaluation of treatment efficacy every 2.cycle
|
24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
pathological response rate, response rate as defined by PET-CT scan, mammography and ultrasound, evaluation of toxicity of the combination regimen
Time Frame: up to 30 weeks
|
up to 30 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Malgorzata K Tuxen, MD, Herlev Hospital, Department of Oncology
- Principal Investigator: Ulla B Tange, MD, Rigshospitalet, Denmark
- Principal Investigator: Soeren Cold, MD, Odense University Hospital
- Principal Investigator: Susanne B Søndergaard, MD, Herlev Hospital
- Principal Investigator: Henrik Petersen, MD, Odense University Hospital
- Principal Investigator: Inger Hoejris, MD, Aarhus University Hospital
- Principal Investigator: Anni Eskild-Jensen, MD, Aarhus University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Antibiotics, Antineoplastic
- Docetaxel
- Cyclophosphamide
- Trastuzumab
- Doxorubicin
- Liposomal doxorubicin
Other Study ID Numbers
Other Study ID Numbers
- PO5903, EudraCT 2008-007951-29
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.